Japanese Journal of Ophthalmology

, Volume 58, Issue 1, pp 75–80 | Cite as

Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy

  • Tatsushi Kawaguchi
  • Yuko Kawazoe
  • Koju Kamoi
  • Masaru Miyanaga
  • Hiroshi Takase
  • Sunao Sugita
  • Manabu Mochizuki
Clinical Investigation



To investigate the clinical course of Behçet’s uveitis patients following discontinuation of infliximab therapy.


This retrospective chart review study examined Behçet’s disease patients who received infliximab treatment between 2000 and 2012. Medical records of patients whose infliximab treatment was discontinued were reviewed, with special focus on the frequency of uveitis attacks in the period before initiation, during treatment and after cessation of the infliximab therapy. Mean visual acuities were evaluated for each treatment period.


Out of the 43 patients treated with infliximab at our uveitis clinic, ten were discontinued due to adverse events or inefficiency. Data for seven patients followed for more than 12 months before initiation and after cessation of infliximab were analyzed. Frequency of acute uveitis attacks was 7.43 per 12 months before initiation of infliximab, 2.86 during treatment and 0.57 after cessation. A statistically higher frequency of uveitis attacks was observed before initiation of infliximab compared to during (p < 0.05) and after cessation of treatment (p < 0.05). There was no statistical significance observed between the period during treatment and after cessation (p = 0.29). The mean logMAR was 0.79 at baseline, 0.68 during treatment, and 0.88 at 12 months after cessation. These differences were not statistically significant.


A satisfactory clinical course with well-controlled ocular inflammation was found after discontinuation of infliximab therapy in Behçet’s uveitis patients. These results suggest that a safe, pre-planned discontinuation of infliximab therapy can be performed in patients with Behçet’s uveitis.


Behçet’s disease Uveitis Infliximab 


  1. 1.
    Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;341:1284–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Nussenblatt RB. Uveitis in Behçet’s disease. Int Rev Immunol. 1997;14:67–79.PubMedCrossRefGoogle Scholar
  3. 3.
    George RK, Chan CC, Whitcup SM, Nussenblatt RB. Ocular immunopathology of Behçet’s disease. Surv Ophthalmol. 1997;42:157–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, et al. Risk and prognostic factors of poor visual outcome in Behçet’s disease. Graefe’s Arch Clin Exp Ophthalmol. 2005;243:1147–52.CrossRefGoogle Scholar
  5. 5.
    Mochizuki M. Immunotherapy for Behçet’s disease. Int Rev Immunol. 1997;14:49–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet’s disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–8.PubMedGoogle Scholar
  8. 8.
    Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease. Int Ophthalmol. 2005;26:83–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behçet’s disease. Jpn J Ophthalmol. 2007;51:53–7.CrossRefGoogle Scholar
  11. 11.
    Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet’s disease. Br J Ophthalmol. 2010;94:284–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Kawaguchi T, Sugita S, Yamada Y, Miyanaga M, Mochizuki M. Regression of optic disc neovascularization in patients with Behçet’s uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther. 2010;26:627–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Okada AA, Goto H, Mochizuki M. Ocular Behçet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H, Fujino Y. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol. 2012;56:536–43.PubMedCrossRefGoogle Scholar
  16. 16.
    Plank SR, Huang XN, Robertson JE, Rosenbaum JT. Cytokine mRNA in rat tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci. 1994;35:924–30.Google Scholar
  17. 17.
    De Vos AF, Van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Tumour necrosis factor-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res. 1995;60:199–207.PubMedCrossRefGoogle Scholar
  18. 18.
    Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211–8.PubMedGoogle Scholar
  19. 19.
    Gül A. Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S6–12.PubMedGoogle Scholar
  20. 20.
    Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behçet uveitis. Am J Ophthalmol. 2006;142:429–34.PubMedCrossRefGoogle Scholar
  21. 21.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.PubMedCrossRefGoogle Scholar
  22. 22.
    Rovere Querini P, Vecellio M, Sabbadini MG, Ciboddo G. Miliary tuberculosis after biological therapy for rheumatoid arthritis. Rheumatology (Oxford). 2002;41:231.PubMedCrossRefGoogle Scholar
  23. 23.
    Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403–12.PubMedCrossRefGoogle Scholar
  24. 24.
    Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1099–100.PubMedCrossRefGoogle Scholar
  25. 25.
    Glück T, Linde HJ, Schölmerich J, Müller-Ladner U, Fiehn C, Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 2002;46:2255–7.PubMedCrossRefGoogle Scholar
  26. 26.
    De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, et al. Club rhumatismes et inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545–51.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Kawazoe Y, Sugita S, Yamada Y, Akino A, Miura K, Mochizuki M. Psoriasis triggered by infliximab in a patient with Behçet’s disease. Jpn J Ophthalmol. 2013;57:95–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–24.PubMedCrossRefGoogle Scholar
  30. 30.
    Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903–12.PubMedCrossRefGoogle Scholar
  31. 31.
    Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161–4.CrossRefGoogle Scholar
  32. 32.
    Adán A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions. Int Ophthalmol. 2010;30:577–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Behçet’s disease research committee of Japan. Behçet’s disease: guide to diagnosis of Behçet’s disease. Jpn J Ophthalmol. 1974;18:291–4.Google Scholar
  34. 34.
    Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata M, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol. 2007;13:5238–44.PubMedGoogle Scholar
  35. 35.
    Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Saleem B, Nizam S, Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol. 2006; 24(6 Suppl 43): S-33-6.Google Scholar
  37. 37.
    Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7:R439–44.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, et al. Safety and efficacy of readministration of infliximab after long-term continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol. 2007;34:510–5.PubMedGoogle Scholar
  39. 39.
    Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M. Induction of regulatory T cells by infliximab in Behçet’s disease. Invest Ophthalmol Vis Sci. 2011;52:476–84.PubMedCrossRefGoogle Scholar
  40. 40.
    Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T-cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204:33–9.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2013

Authors and Affiliations

  • Tatsushi Kawaguchi
    • 1
    • 2
  • Yuko Kawazoe
    • 2
  • Koju Kamoi
    • 2
  • Masaru Miyanaga
    • 2
  • Hiroshi Takase
    • 2
  • Sunao Sugita
    • 2
    • 3
  • Manabu Mochizuki
    • 2
  1. 1.Department of OphthalmologyTokyo Metropolitan Cancer and Infectious Disease Center Komagome HospitalBunkyoJapan
  2. 2.Department of Ophthalmology and Visual ScienceTokyo Medical and Dental University, Graduate School of Medical and Dental SciencesBunkyoJapan
  3. 3.Laboratory for Retinal RegenerationRIKEN Center for Developmental BiologyChuoJapan

Personalised recommendations